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Protein tyrosine phosphatase 1B (PTP1B) inhibitor has been suggested that it 
plays a main function in the negative regulation of insulin and leptin signaling, 
thereby making it for a treatment of diabetes mellitus type 2 and obesity. 
Moreover, previously conducted research in breast cancer showed that 
overexpression of PTP1B is detected when selective PTP1B inhibition occurs. As 
part of our ongoing studies for new PTP1B inhibitor agents from medicinal plants, 
relative mass defect (RMD) analysis was applied to select the extensive range of 
triterpenoids in complex plant extracts. The rapid identification and specific 
metabolite classes of novel plant metabolites could be achieved by calculating 
RMDs from molecular and fragment ions. Therefore, three new triterpenoids (1 - 
3) and seventeen previously reported triterpenoids (4  20) were isolated from a 
50% EtOH extract of Cleistocalyx operculatus (Roxb.) Merr. et L.M. Perry. Their 
structures were determined on the basis of extensive spectroscopic analysis as well 
as comparison with previous data. All isolates were evaluated for their inhibitory 
effects on PTP1B. Compound 6 showed strong inhibitory effects while 
compounds 3, 7, 9, 10, 19 and 20 showed moderate inhibitory effects of on PTP1B 
enzyme.  
Keywords: Cleistocalyx operculatus, Myrtaceae, triterpenoid, relative mass 
defects (RMDs), protein tyrosine phosphatase 1B (PTP1B) 
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1. Obesity and type 2 diabetes  
Obesity and type 2 diabetes have been emerged as one of the major pandemics 
to human health in the 21st centrury (Zimmet et al., 2001; Morris et al., 2015). The 
population in worldwide with diabetes has risen to 422 million in 2014, and it was 
estimated the prevalence of the global diabetes to reach over 366 million in 2030. 
According to the data from the Emerging Risk Factors Collaboration, around 1.6 
million deaths were directly brought about by diabetes in 2015 (Mather et al., 2006). 
Some experts called “diabesity” as dual epidemic, the growth in the disseminate of 
the diabetes parallels that of obesity, and those are crucial causes of blindness, kidney 
failure, heart attacks, stroke, and high blood glucose (WHO, 2017). The world direct 
annual cost of diabetes is more than 825 million by cost estimates from a recent 
systematic review (NCD RisC., 2016). Although anti-diabetes candidates has 
continued to develop for the clinic, it is hard for many people to attain HbA1C target 
levels. Developing that new anti-diabetes agent is necessary with these insufficient 
opportunities to get therapy.  
 
Figure 1. Illustration of PTP1B Pathway 
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2. Protein tyrosine phosphatases 1B (PTP1B) and its purpose of study 
Protein tyrosine phosphatases 1B (PTP1B) of PTPs plays a significant role in 
the intracellular signaling by dephosphorylating tyrosine residues, and it exhibited 
increased sensitivity to insulin and resistance to diabetes and obesity (Na et al., 2007). 
PTP1B, a negative regulators of insulin signaling, has critical roles in the insulin 
pathway among the many PTPs such as PTP-a, SH2-domain-containing 
phosphotyrosine phosphatase (SHP2), and leukocyte antigen-related tyrosine 
phosphatase (LAR) (Nguyen et al., 2013). While PTP1B knockout mice show 
enhanced the level of insulin sensitivity and glucose homeostasis, PTP1B 
overexpression was observed to negatively regulates the IR signaling cascade and 
increased in insulin-resistant states (Uddin et al., 2014). Thus, PTP1B inhibitors 
could be useful for treating both type 2 diabetes and obesity.  
 
3. Relative mass defect (RMD) analysis and its application 
Relative mass defect, called RMD, is one of the mass defect filtering methods, 
which is usually refers to the deviation of a specific constituent’s exacted mass from 
its nominal mass. The absolute mass defect reflects the ion’s elemental composition 
that the reason is why each element has an appropriate mass defect, and it denotes 
the sum of the mass defects for all atoms in the molecule. Thus, mass measurement 
accuracy is frequently insufficient to provide well-defined formula assignments 
among higher molecular weight compounds with large error (Ekanayaka et al., 2015). 
However, the RMD reveals the fractional hydrogen content of a specific compound 
in naturally occurring metabolites that leads to classify ions in a mass spectrum by 
their relative mass defect (Sleno L., 2012). Each compound class usually has a set 
trend of mass defect with increasing mass. Although most elements have negative 
mass defects because of increasing nuclear binding energy with atomic number, 
hydrogen has the remarkable source for increasing the values of mass defect, +7.825 
mDa, and it has a main contribution to the mass defect. RMD is calculated by 
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dividing mass defect by the monoisotopic mass multiplied by 106 because of ppm 
expression (Ekanayaka et al., 2015), so specific RMD ranges recognize as different 
compound classes. Therefore, it is convenient for the rapid identification of novel 
plant and assignments of newly discovered substances to natural product classes.  
 
4. Cleistocalyx operculatus (Roxb.) Merr. et L.M. Perry. (Mytaceae) 
The genus Cleistocalyx (Mytaceae) includes approximately 37 species, and was 
distributed in all around world. The most popular species, Clesitocalyx operculatus 
(Roxb. Merr. et L.M. Perry, commonly named “Voi” in Vietnamese and “Shui Rong 
(水榕)” in Chinese, is a famous evergreen plant that is spread throughout various 
Asia regions such as China, Vietnam and even northern territory of Australia (Dung 
et al., 2009). The plant has a long history of uses of beverage at the Vietnam and 
China as a traditional herbal tea and a medicine for the treatment of cold, fever, 
dysentery, vomiting, indigestion, gastrointestinal disorder, and inflammation (Ha et 
al., 2016). The chemical constituents, including chalcone, flavanones, flavones, and 
oleanane- and ursane- type triterpenoids, have been discovered in this plant’s buds 
with variety of biological activities such as cancer cell growth inhibition and 
cholinesterase inhibition as well as anti-oxidation, anti-hyperglycemia, anti-
influenza, and anti-inflammation (Ha et al., 2016). However, there are still few 
studies on its leaves. Taraxastane-type triterpene, acetophenone, flavanone, and 
pentacyclic triterpenoids were discovered from the leaves of this plant (Wang et al., 
2016). The present study was to provide better understanding about the 
phytochemical profile of C. operculatus leaves. Its biologically active compounds 
were introduced from the natural sources as ethno-medicines. In addition, its 





II. Materials and Methods 
1. Plant materials 
The leaves of C. Operculatus were purchased from a market in My Duc district, 
Hanoi, Vietnam in February 2017 and were identified botanically by Prof. Won Keun 
Oh, College of Pharmacy, Seoul National University, Seoul, Korea. A voucher 
specimen (SNU2017-02) was deposited at the Laboratory of Pharmacognosy, 
College of Pharmacy, Seoul National University, Republic of Korea.  
 
2. Chemicals, reagents and chromatography 
2-1. Chemical reagents 
- All solvents used for extraction and isolation (n-hexane, EtOAc, n-BuOH, acetone, 
MeOH, EtOH, and MeCN) were of analytical grade and HCl and H2SO4 for 
extraction, fractionation, and isolation from Daejung Chemical & Metals (Korea).  
- Formic acid was purchased from Sigma Aldrich (USA). 
- NMR solvents (chloroform-d, methanol-d4, DMSO-d6, and pyridine-d5) were 
purchased from Cambridge Isotope Laboratories (USA). 
- NP silica gel (40-63 µm and 63-200 µm) from ZEOchem AG (Switzerland). 
- RP silica gel Cosmosil 75C18-PREP was purchased from Nacalai Tesque (Japan). 
- Sephadex LH-20 (18-111 µm) was purchased from GE Healthcare (USA). 
- Solvents used for HPLC chromatography (MeCN and MeOH) were purchased from 
Daejung chemical & Metals (Korea).  
- TLC Silica gel 60 F254 (20 x 20 cm plate) and TLC Silica gel 60 RP-18 F254S (20 x 
20 cm plate) were used from Merck Millipore (USA).  
 
2-2. Bioassay reagents 
- Citrate, EDTA, and p-NPP were purchased from Sigma-Aldrich (USA). 
- DTT was purchased from Roche Diagnostics (USA). 
- PTP1B was obtained from BIOMOL International LP (USA). 
- Sodium chloride was purchased from OCI Company (Korea). 
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- Sodium hydroxide was purchased from Junsei Chemical (Japan).  
 
3. Experimental instruments 
- Analytical balance: BSA 2245-CW from Sartorius (Germany). 
- Autoclave: LAC-5080S from LAB Tech. (Korea). 
- Centrifuge (for filtration): AVANTI J2 from Beckman Coulter (USA). 
         (for bioassay): FLETA S from Hanil Science (Korea). 
- Clean bench: Class II Biological Safety Cabinet from Esco (Korea). 
- CO2 incubator: Forma Series II water jacketed CO2 incubator from THERMO 
(USA) 
- Drying oven: WFO-700 from EYELA (Japan). 
- ELISA Microplate reader: VersaMax from Molecular Devices (USA). 
- ESIMS spectrometer: 6130 Quadrupole MS/Agilent, 1260 Infinity from Agilent 
(USA). 
- ESIMS column: Inno C18 column (4.6 mm × 250 mm, 5μm particle size), Young 
Jin Biochrom (Korea). 
- Evaporator: KSB-202 from EYELA (Japan). 
- Fraction collector: Advantec 2120 from Waters (USA).  
- HRESIMS/MS spectrometer: 6530 Q-TOF spectrometer from Agilent (USA). 
- HPLC column: Optima Pak C18 column (10  250 mm, 5 µm particle size) from 
RS Tech (Korea). 
- HPLC system : 321 pump and  Gilson UV/VIS 155 detector from Gilson (USA). 
- IR spectrometer: JASCO, FT/IR-4200 from Jasco (USA). 
- NMR spectrometers 
 Varian Gemini 2000, 300 MHz spectrometer from Agilent (USA). 
 AVANCE digital 400 spectrometer from Bruker (Germany). 
 AVANCE digital 500 spectrometer from Bruker (Germany). 
 JNM-ECA-600 spectrometer from JEOL (USA). 
 AVANCE digital 800 spectrometer from Bruker (Germany). 
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- Polarimeter: P-2000 with a 10-mm cell from JASCO (USA). 
- Shaking incubator: BF-60SIR from BioFree (Korea) 
- Sonicator: Powersonic 420, Hwa Shin Tech. (Korea). 
- UV lamp: VL-4.LC from Vilber Lourmat (France). 
- Water purification system Direct-Q®  & Direct-Q UV from Merck (Germany). 
 
4. Extraction and isolation schemes 
4-1. Extraction and fractionation of C. operculatus leaves 
Air dried leaves of C. operculatus (2.5 kg) were ground and extracted with 50% 
aqueous EtOH for the three times at 60 °C for a period of eight hours ultra-sonication. 
The crude extract (478.7 g) was suspended in distilled water (2 L) and was 
completely partitioned with n-hexane and n-BuOH (each 2 L x 3 times) to obtain 
three fractions. Each fraction was evaporated under low pressure to dry, and 44.2 g 
of n-heaxane-soluble (1.77 % of dried leaves, w/w), 351.5 g of n-BuOH-soluble 
(14.06 % of dried leaves, w/w), and 65.3 g of water-soluble (2.61 % of dried leaves, 




























4-2. Isolation scheme of n-BuOH-soluble fraction 
n-BuOH residue (351.5 g) contains a large amount of mixed triterpenoids 
checked by RMD profiling. The further isolation steps were proceeded as 
dereplication processes monitored by LC-MS profile. This bioactive n-BuOH 
fraction was chromatographed on a NP silica gel (60-200 mesh) column with a 
stepwise gradients of n-hexane/EtOAc [9:1, 1:1, 0:1, MeOH100%; v/v] as eluant to 
yield 9 fractions (N1-9). By TLC and LC/MS profiles, the fractions from N1 to N5 
contain numerous less oxygenated aglycones of chalcones, flavonoids, and 
triterpenoids. On the other hand, the more oxygenated compounds were included on 
the fractions from N6 to N9. 
N4 has undergone recrystallization and filtered out by vacuum filtration. The 
crystal part was directly purified by HPLC [RS Tech Optima Pak C18 column (10 × 
250 mm, 5 μm particle size)]; mobile phase MeCN in H2O containing 0.1% HCO2H 
(0−43 min: 85-100% MeCN, 43-54 min: 100% MeCN); flow rate 2 mL/min; UV 
detection at 205 and 254 nm] to yield compounds 6 (tR =  27.0 min, 3.5 mg) and 7 
(tR = 32.0 min, 14.9 mg). The residue of N4 was also applied to the same system 
above to isolate compound 4 (tR = 18.0 min, 11.3 mg), and 11 (tR = 52.0 min, 5.3 mg) 








Scheme 2. Isolation scheme of n-BuOH fraction of C. operculatus leaves 
n-BuOH soluble fraction 
(351.5 g)
N4 N7 N8
Step gradient silica gel CC






















































































Another fraction, N5, was chromatographed over a RP-C18 (4 × 40 cm; 75 μm 
particle size) Open CC and eluted with a stepwise gradient of MeOH/H2O (1:1 to 
1:0) to afford 4 subfractions (N5.1-N5.4). N5.1 was further applied to HPLC [RS 
Tech Optima Pak C18 column (10 × 250 mm, 5 μm particle size)]; mobile phase 
MeCN in H2O containing 0.1% HCO2H (0−23 min: 83% MeCN, 23-33 min: 100% 
MeCN); flow rate 2 mL/min; UV detection at 205 and 254 nm] to yield compound 
18 (tR = 12.0 min, 3.8 mg). N5.3 fraction was also purified by same method above 
to isolate compounds, 9 (tR = 15.0 min, 11.6 mg), 19 (tR = 19.0 min, 6.4 mg) and 20 
(tR = 16.5 min, 3.9 mg). N5.2 fraction was purified by HPLC [RS Tech Optima Pak 
C18 column (10 × 250 mm, 5 μm particle size)]; mobile phase MeCN in H2O 
containing 0.1% HCO2H (0−25 min: 70 % MeCN, 25-35 min: 100% MeCN); flow 
rate 2 mL/min; UV detection at 205 and 254 nm] to yield compounds 16 (tR = 23.0 
min, 47.5 mg) and 17 (tR = 14.5 min, 4.3 mg) (See scheme 2). 
Fraction N7 was further subjected to RP-C18 (4 × 40 cm; 75 μm particle size) 
Open CC and eluted with a stepwise gradient of MeOH/H2O (1:1 to 1:0) to afford 9 
subfractions (N7.1-N7.9). N7.4 fraction was applied to Sephadex LH-20 (18 – 111 
μm) with MeOH/H2O (1:1 to 1:0) to afford 3 fractions monitored by TLC and 
LC/MS profile. N7.4.2 as a rich triterpenoids’ fraction further applied to semi-
preparative HPLC [RS Tech Optima Pak C18 column (10 × 250 mm, 5 μm particle 
size)]; mobile phase MeCN in H2O containing 0.1% HCO2H (0−43 min: 52 % MeCN, 
43-52 min: 100% MeCN); flow rate 2 mL/min; UV detection at 205 and 254 nm] to 
yield 2 (tR = 28.0 min, 17.6 mg), 12 (tR = 32.0 min, 26.9 mg), and 13 (tR = 19.0 min, 
12.6 mg). The compound 14 (tR = 28.5 min, 23.7 mg) was isolated from N7.7 by 
HPLC [RS Tech Optima Pak C18 column (10 × 250 mm, 5 μm particle size)]; mobile 
 
11 
phase MeCN in H2O containing 0.1% HCO2H (0−30 min: 36-51 % MeCN, 30-40 
min: 100% MeCN); flow rate 2 mL/min; UV detection at 205 and 254 nm] (See 
scheme 2). 
The chromatographic purification of N8 fraction by Sephadex LH-20 (18 – 111 
μm) with MC/MeOH (1:1 to 0:1) to obtain a rich triterpenoid fraction (N8.4). It was 
further subjected to ODS Open CC and eluted with a stepwise gradient of 
MeCN/H2O (1:1 to 1:0) to afford 7 sub-fractions (N8.4.1-N8.4.7). Compound 3 (tR 
= 34.0 min, 9.4 mg), 10 (tR =  10.5 min, 8.5 mg), and 15 (tR = 28.0 min, 7.5 mg) were 
purified by HPLC [RS Tech Optima Pak C18 column (10 × 250 mm, 5 μm particle 
size)]; mobile phase MeCN in H2O containing 0.1% HCO2H (0−40 min: 50-75 % 
MeCN, 40-50 min: 100% MeCN); flow rate 2 mL/min; UV detection at 205 and 254 
nm] from N8.4.5 fraction. Fraction N8.4.4 was chromatographed over HPLC [RS 
Tech Optima Pak C18 column (10 × 250 mm, 5 μm particle size)]; mobile phase 
MeOH in H2O containing 0.1% HCO2H (0−40 min: 70-83 % MeOH, 41-50 min: 
100% MeOH); flow rate 2 mL/min; UV detection at 205 and 254 nm] to yield the 
compound 5 (tR = 16.0 min, 9.9mg) and compound 8 (tR = 41.0 min, 4.5 mg). While 
compound 1 (tR = 39.0 min, 11.7 mg) was purified from HPLC [RS Tech Optima 
Pak C18 column (10 × 250 mm, 5 μm particle size)]; mobile phase MeOH in H2O 
containing 0.1% HCO2H (0−40 min: 55-63 % MeOH, 41-50 min: 100% MeOH); 






4-3. Chemical and spectral properties of isolated compounds 
4-3-1. Compound 1 
Brownish gum; []𝐷
20 -20.8 (c 0.3, MeOH); UV λmax (MeOH) (log ɛ) (nm) 
194 (2.95), 224 (1.96); IR (KBr) νmax (cm–1) 3364, 2946, 2871, 2359, 1706, 1697, 
1451, 1389, 1219, 1032; ESIMS m/z 539.3 [M+Na]+, 471.3 [M-HCOO]+, 481.3 
[M-2H2O+H]+, 515.3 [M-H]-; HRESIMS m/z 515.3379 [M-H]- (calcd for C31H48O6 




4-3-2.  Compound 2  
White amorphous powder; []𝐷
20 +81.9 (c 0.3, MeOH); UV λmax (MeOH) 
(log ɛ) (nm) 196 (3.16); IR (KBr) νmax (cm–1) 3365, 2924, 1775, 1647, 1356, 1218, 
1149, 1057, 1033; ESIMS m/z 469.3 [M+H]+, 451.3 [M-H2O+H]+, 491.2 [M+Na]+, 
513.3 [M+HCOO]-; HRESIMS m/z 513.2856 [M+HCOO]- (calcd for C29H40O5 




4-3-3. Compound 3 
White amorphous powder; []𝐷
20 +4.2 (c 0.3, MeOH); UV λmax (MeOH) (log 
ɛ) (nm) 196 (2.85) 226 (2.28); IR (KBr) νmax (cm–1) 3245, 2934, 2889, 2359, 2342, 
1718, 1680, 1641, 1452, 1212, 1167, 1033; ESIMS m/z 539.3 [M+Na]+, 471.3 [M-
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HCOO]+, 453.3 [M-H2O-HCOO]+, 515.3 [M-H]-; HRESIMS m/z 515.3381 [M-H]- 
(calcd for C29H40O5 515.3378); see Table 1 for 1H NMR (600 MHz, pyridine-d5) 
and 13C NMR (150 MHz, pyridine-d5). 
 
 
4-3-4. Compound 4 
White amorphous powder; []𝐷
20 +5.0 (c 0.3, MeOH); UV λmax (MeOH) (log 
ɛ) (nm) 194 (2.17) 226 (2.33); IR (KBr) νmax (cm–1) 3388, 2966, 2873, 2359, 1704, 
1680, 1658, 1643, 1641, 1453, 1165, 1015; ESIMS m/z 501.3 [M+H]+, 483.3 [M-
H2O+H]+, 455.3 [M-HCOO]+, 437.3 [M-H2O-HCOO]+, 499.3 [M-H]-, 567.3 [M-
H+HCOONa]-. 
1H NMR (800 MHz, pyridine-d5, δ in ppm) : δ 5.05 (1 H, br s, H-29a), δ 4.83 
(1 H, br s, H-29b), δ 3.77 (3 H, s, -OCH3-28), δ 3.51 (1 H, td, J= 4.0, 11.8 Hz, H-
19), δ 3.25 (1 H, dd, J= 4.7, 10.9 Hz, H-3), δ 2.12 (1 H, t, J= 11.0 Hz, H-18), δ 
1.90 (3 H, s, CH3-30), δ 1.18 (3 H, s, CH3-26), δ 1.08 (3 H, s, CH3-23), δ 1.01 (3 H, 
s, CH3-24), δ 0.92 (3 H, s, CH3-25). 
13C NMR (200 MHz, pyridine-d5, δ in ppm) : δ 39.8 (C-1), δ 28.8 (C-2), δ 
78.3 (C-3), δ 39.9 (C-4), δ 56.5 (C-5), δ 19.3 (C-6), δ 38.8 (C-7), δ 41.3 (C-8), δ 
52.2 (C-9), δ 38.3 (C-10), δ 21.7 (C-11), δ 27.3 (C-12), δ 40.7 (C-13), δ 60.3 (C-
14), δ 29.0 (C-15), δ 35.4 (C-16), δ 57.2 (C-17), δ 52.9 (C-18), δ 48.1 (C-19), δ 
151.1 (C-20), δ 31.3 (C-21), δ 37.7 (C-22), δ 29.0 (C-23), δ 17.0 (C-24), δ 17.5 (C-






4-3-5. Compound 5 
White amorphous powder; []𝐷
20 +14.4 (c 0.3, MeOH); UV λmax (MeOH) 
(log ɛ) (nm) 208 (2.38); IR (KBr) νmax (cm–1) 3335, 2928, 2876, 2359, 1687, 1457, 
1389, 1271, 1157, 1049, 1033; ESIMS m/z 527.3 [M+Na]+, 469.3 [M-2H2O+H]+, 
451.3 [M-3H2O+H]+, 503.3 [M-H]-. 
1H NMR (600 MHz, pyridine-d5, δ in ppm) : δ 5.60 (1 H, br s, H-12), δ 4.27 
(1 H, td, J= 4.3, 9.7 Hz, H-2), δ 4.22 (1 H, m, H-3), δ 4.21 (1 H, d, J= 10.1 Hz, H-
23b), δ 3.73 (1 H, d, J= 10.5 Hz, H-23a), δ 3.06 (1 H, s, H-18), δ 1.67 (3 H, s, CH3-
29), δ 1.43 (3 H, s, CH3-27), δ 1.14 (3 H, s, CH3-25), δ 1.13 (3 H, d, J= 6.6 Hz, 
CH3-30) , δ 1.11 (3 H, s, CH3-26) , δ 1.09 (3 H, s, CH3-24). 
13C NMR (150 MHz, pyridine-d5, δ in ppm) : δ 48.3 (C-1), δ 69.4 (C-2), δ 
78.8 (C-3), δ 44.1 (C-4), δ 48.5 (C-5), δ 19.2 (C-6), δ 33.7 (C-7), δ 41.0 (C-8), δ 
48.3 (C-9), δ 38.9 (C-10), δ 24.7 (C-11), δ 128.5 (C-12), δ 140.5 (C-13), δ 42.7 (C-
14), δ 29.8 (C-15), δ 26.9 (C-16), δ 48.8 (C-17), δ 55.1 (C-18), δ 73.2 (C-19), δ 
42.9 (C-20), δ 27.4 (C-21), δ 39.0 (C-22), δ 67.1 (C-23), δ 14.8 (C-24), δ 17.3 (C-
25), δ 17.9 (C-26), δ 27.6 (C-27), δ 181.2 (C-28), δ 25.2 (C-29), δ 17.8 (C-30). 
 
 
4-3-6. Compound 6 
White amorphous powder; []𝐷
20 -4.3 (c 0.3, MeOH); UV λmax (MeOH) (log 
ɛ) (nm) 196 (3.00); IR (KBr) νmax (cm–1) 3398, 2994, 2941, 2868, 2359, 2341, 
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1681, 1641, 1452, 1236, 1033, 1012; ESIMS m/z 439.3 [M-H2O+H]+, 455.4 [M-
H]-. 
1H NMR (300 MHz, pyridine-d5, δ in ppm) : δ 4.96 (1 H, br s, H-29a), δ 4.79 
(1 H, br s, H-29b), δ 3.55 (1 H, m, H-19), δ 3.47 (1 H, dd, J= 8.7, 7.4 Hz, H-3), δ 
2.75 (1 H, td, J= 2.9, 11.4 Hz, H-13), δ 1.81 (3 H, s, CH3-30), δ 1.24 (3 H, s, CH3-
23), δ 1.09 (3 H, s, CH3-27), δ 1.08 (3 H, s, CH3-24), δ 1.03 (3 H, s, CH3-26), δ 
0.84 (3 H, s, CH3-25). 
13C NMR (75 MHz, pyridine-d5, δ in ppm) : δ 39.5 (C-1), δ 28.3 (C-2), δ 
78.1 (C-3), δ 39.3 (C-4), δ 55.9 (C-5), δ 18.8 (C-6), δ 34.8 (C-7), δ 41.1 (C-8), δ 
51.0 (C-9), δ 37.5 (C-10), δ 21.2 (C-11), δ26.1 (C-12), δ 38.6 (C-13), δ 42.8 (C-
14), δ 30.3 (C-15), δ 32.9 (C-16), δ 56.6 (C-17), δ 49.7 (C-18), δ 47.8 (C-19), δ 
151.3 (C-20), δ 31.2 (C-21), δ 37.6 (C-22), δ 28.7 (C-23), δ 16.4 (C-24), δ 16.4 (C-
25), δ 16.3 (C-26), δ 14.9 (C-27), δ 178.9 (C-28), δ 109.9 (C-29), δ 19.5 (C-30). 
 
 
4-3-7. Compound 7 
White amorphous powder; []𝐷
20 +43.6 (c 0.3, MeOH); UV λmax (MeOH) 
(log ɛ) (nm) 196 (2.56); IR (KBr) νmax (cm–1) 3393, 2937, 2865, 2359, 2348, 1688, 
1460, 1386, 1048, 1033; ESIMS m/z 439.3 [M-H2O+H]+, 455.4 [M-H]-. 
1H NMR (400 MHz, chloroform-d, δ in ppm) : δ 5.27 (1 H, t-like s, H-12), δ 
3.21 (1 H, dd, J= 3.8, 10.5 Hz, H-3), δ 2.82 (1 H, dd, J= 4.0, 14.1 Hz, H-18), δ 1.13 
(3 H, s, CH3-27), δ 0.98 (3 H, s, CH3-23), δ 0.92 (3 H, s, CH3-30), δ 0.91 (3 H, s, 
CH3-29), δ 0.90 (3 H, s, CH3-25), δ 0.77 (3 H, s, CH3-24) , δ 0.74 (3 H, s, CH3-26). 
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13C NMR (100 MHz, chloroform-d, δ in ppm) : δ 38.5 (C-1), δ 28.2 (C-2), δ 
79.2 (C-3), δ 38.9 (C-4), δ 55.3 (C-5), δ 18.4 (C-6), δ 32.6 (C-7), δ 39.4 (C-8), δ 
47.8 (C-9), δ 37.2 (C-10), δ 23.5 (C-11), δ 122.8 (C-12), δ 143.8 (C-13), δ 41.1 (C-
14), δ 27.3 (C-15), δ 23.0 (C-16), δ 46.7 (C-17), δ 41.7 (C-18), δ 46.0 (C-19), δ 
30.8 (C-20), δ 33.9 (C-21), δ 33.2 (C-22), δ 27.8 (C-23), δ 15.7 (C-24), δ 15.5 (C-
25), δ 17.3 (C-26), δ 26.1 (C-27), δ 183.6 (C-28), δ 32.7 (C-29), δ 23.7 (C-30). 
 
 
4-3-8. Compound 8 
White amorphous powder; []𝐷
20 +9.3 (c 0.3, MeOH); UV λmax (MeOH) (log 
ɛ) (nm) 190 (1.99) 224 (0.99); IR (KBr) νmax (cm–1) 3366, 2937, 2864, 2360, 1748, 
1049, 1033; ESIMS m/z 489.3 [M+H]+, 511.3 [M+Na]+, 533.4 [M+HCOO]-. 
1H NMR (600 MHz, pyridine-d5, δ in ppm) : δ 4.20 (1 H, br s, H-12), δ 4.13 
(1 H, td, J= 4.5, 11.2 Hz, H-2), δ 3.38 (1 H, d, J= 9.4 Hz, H-3), δ 1.61 (3 H, s, CH3-
27), δ 1.35 (3 H, s, CH3-26), δ 1.29 (3 H, s, CH3-23), δ 1.12 (3 H, s, H-24) , δ 1.02 
(3 H, s, CH3-25), δ 0.92 (3 H, s, CH3-30), δ 0.82 (3 H, s, CH3-29). 
13C NMR (125 MHz, pyridine-d5, δ in ppm) : δ 48.6 (C-1), δ 69.2 (C-2), δ 
84.2 (C-3), δ 40.4 (C-4), δ 56.4 (C-5), δ 18.9 (C-6), δ 34.9 (C-7), δ 43.2 (C-8), δ 
45.6 (C-9), δ 38.6 (C-10), δ 30.0 (C-11), δ 76.2 (C-12), δ 92.0 (C-13), δ 43.3 (C-
14), δ 28.8 (C-15), δ 22.2 (C-16), δ 45.5 (C-17), δ 52.1 (C-18), δ 40.0 (C-19), δ 
32.1 (C-20), δ 35.0 (C-21), δ 28.8 (C-22), δ 29.7 (C-23), δ 17.9 (C-24), δ 18.4 (C-





4-3-9. Compound 9 
White amorphous powder; []𝐷
20 +32.3 (c 0.3, MeOH); UV λmax (MeOH) 
(log ɛ) (nm) 196 (2.83); IR (KBr) νmax (cm–1) 3392, 2940, 2864, 2359, 1704, 1688, 
1052, 1033; ESIMS m/z 495.3 [M+Na]+, 409.3 [M-H2O-HCOO]+, 471.3 [M-H]-. 
1H NMR (400 MHz, pyridine-d5, δ in ppm) : δ 5.49 (1 H, t, J= 3.2 Hz, H-
12), δ 4.12 (1 H, m, H-2), δ 3.42 (1 H, d, J= 9.4 Hz, H-3), δ 3.31 (1 H, dd, J= 3.8, 
13.6 Hz, H-18), δ 1.29, 1.28, 1.10, 1.04, 1.02, 1.01, 0.97 (each 3 H, s). 
13C NMR (100 MHz, pyridine-d5, δ in ppm) : δ 48.2 (C-1), δ 69.1 (C-2), δ 
84.3 (C-3), δ 40.3 (C-4), δ 56.4 (C-5), δ 19.3 (C-6), δ 33.8 (C-7), δ 40.4 (C-8), δ 
48.6 (C-9), δ 39.0 (C-10), δ 24.4 (C-11), δ 123.0 (C-12), δ 145.3 (C-13), δ 42.7 (C-
14), δ 28.8 (C-15), δ 24.2 (C-16), δ 47.2 (C-17), δ 42.5 (C-18), δ 46.9 (C-19), δ 
31.4 (C-20), δ 34.7 (C-21), δ 33.7 (C-22), δ 29.8 (C-23), δ 17.3 (C-24), δ 18.0 (C-
25), δ 18.2 (C-26), δ 26.7 (C-27), δ 180.7 (C-28), δ 33.7 (C-29), δ 24.2 (C-30). 
 
 
4-3-10. Compound 10 
White amorphous powder; []𝐷
20 -5.8 (c 0.3, MeOH); UV λmax (MeOH) (log 
ɛ) (nm) 196 (2.81) 226 (2.26); IR (KBr) νmax (cm–1) 3384, 2943, 2868, 2845, 2359, 
2842, 1705, 1689, 1508, 1375, 1052, 1033; ESIMS m/z 495.3 [M+Na]+, 409.3 [M-
H2O-HCOO]+, 471.3 [M-H]-. 
1H NMR (800 MHz, pyridine-d5, δ in ppm) : δ 4.92 (1 H, br s, H-29b), δ 
4.75 (1 H, br s, H-29a), δ 4.08 (1 H, td, J= 4.4, 9.6 Hz, H-2), δ 3.51 (1 H, td, J= 
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5.4, 10.9 Hz, H-19), δ 3.38 (1 H, d, J= 9.4 Hz, H-3), δ 2.70 (1 H, td, J= 3.4, 12.4 
Hz , H-13), δ 2.60 (1 H, dt, J= 3.0, 12.7 Hz , H-16), δ 2.30 (1 H, dd, J= 4.6, 12.5 
Hz , H-1), δ 1.76 (3 H, s, CH3-30), δ 1.24 (3 H, s, CH3-23) , δ 1.04 (3 H, s, CH3-
24) , δ 1.03 (3 H, s, CH3-26) , δ 1.03 (3 H, s, CH3-27), δ 0.89 (3 H, s, CH3-25). 
13C NMR (200 MHz, pyridine-d5, δ in ppm) : δ 48.7 (C-1), δ 69.3 (C-2), δ 
84.3 (C-3), δ 40.4 (C-4), δ 56.5 (C-5), δ 19.3 (C-6), δ 35.2 (C-7), δ 41.6 (C-8), δ 
51.4 (C-9), δ 38.1 (C-10), δ 21.8 (C-11), δ 26.5 (C-12), δ 39.2 (C-13), δ 43.3 (C-
14), δ 30.7 (C-15), δ 33.3 (C-16), δ 57.1 (C-17), δ 50.2 (C-18), δ 48.2 (C-19), δ 
151.8 (C-20), δ 31.6 (C-21), δ 39.0 (C-22), δ 29.7 (C-23), δ 18.0 (C-24), δ 18.1 (C-
25), δ 16.9 (C-26), δ 15.3 (C-27), δ 179.3 (C-28), δ 110.5 (C-29), δ 19.9 (C-30). 
 
 
4-3-11. Compound 11 
White amorphous powder; []𝐷
20 +53.6 (c 0.3, MeOH); UV λmax (MeOH) 
(log ɛ) (nm) 198 (2.58) 228 (1.86); IR (KBr) νmax (cm–1) 3335, 2923, 2862, 2359, 
2342, 1460, 1362, 1047, 1033, 1006. 
1H NMR (600 MHz, chloroform-d, δ in ppm) : δ 5.20 (1 H, t, J= 3.6 Hz, H-
12), δ 3.56 (1 H, d, J= 10.9 Hz, H-28), δ 3.23 (1 H, dd, J= 11.3 Hz, H-3), δ 3.21 (1 
H, d, J= 10.9 Hz, H-28), δ 1.98 (1 H, dd, J= 4.3, 13.4 Hz, H-18), δ 1.16 (3 H, s, H-
27), δ 0.99 (3 H, s, CH3-23), δ 0.94 (3 H, s, CH3-26), δ 0.93 (3 H, s, H-25), δ 0.89 
(3 H, s, CH3-29) , δ 0.87 (3 H, s, CH3-30) , δ 0.79 (3 H, s, CH3-24). 
13C NMR (150 MHz, chloroform-d, δ in ppm) : δ 38.7 (C-1), δ 27.4 (C-2), δ 
79.2 (C-3), δ 38.9 (C-4), δ 55.3 (C-5), δ 18.5 (C-6), δ 32.7 (C-7), δ 39.9 (C-8), δ 
47.7 (C-9), δ 37.1 (C-10), δ 23.7 (C-11), δ 122.5 (C-12), δ 144.4 (C-13), δ 41.9 (C-
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14), δ 25.7 (C-15), δ 22.2 (C-16), δ 37.1 (C-17), δ 42.5 (C-18), δ 46.6 (C-19), δ 
31.1 (C-20), δ 34.2 (C-21), δ 31.2 (C-22), δ 28.2 (C-23), δ 15.7 (C-24), δ 15.7 (C-
25), δ 16.9 (C-26), δ 26.1 (C-27), δ 69.9 (C-28), δ 33.3 (C-29), δ 23.7 (C-30). 
 
 
4-3-12. Compound 12 
White amorphous powder; []𝐷
20 +54.0 (c 0.3, MeOH); UV λmax (MeOH) 
(log ɛ) (nm) 194 (3.00); IR (KBr) νmax (cm–1) 3388, 2870, 2843, 2359, 1772, 1761, 
1650, 1451, 1360, 1137, 1057, 1017; ESIMS m/z 471.3 [M+H]+, 493.2 [M+Na]+, 
515.4 [M+HCOO]-. 
1H NMR (800 MHz, pyridine-d5, δ in ppm) : δ 5.88 (1 H, br s, H-23b), δ 
4.98 (1 H, br s, H-23a), δ 4.36 (1 H, dt, J= 1.9, 8.8 Hz, H-3), δ 4.12 (1 H, m, H-2), 
δ 3.33 (1 H, dd, J= 2.4, 3.4 Hz, H-11), δ 3.11 (1 H, d, J= 3.8 Hz, H-12), δ 2.62 (1 
H, dd, J= 4.9, 12.6 Hz, H-1b), δ 1.85 (1 H, d, J= 11.7 Hz, H-18), δ 1.78 (1 H, m, H-
5), δ 1.70 (1 H, m, H-1a), δ 1.34 (3 H, d, J= 6.2 Hz, H-29), δ 1.18 (3 H, s, CH3-26), 
δ 1.17 (3 H, s, CH3-27), δ 0.92 (3 H, d, J= 6.5 Hz, H-30), , δ 0.91 (3 H, s, CH3-25). 
13C NMR (200 MHz, pyridine-d5, δ in ppm) : δ 48.2 (C-1), δ 73.7 (C-2), δ 
79.9 (C-3), δ 151.9 (C-4), δ 50.3 (C-5), δ 21.2 (C-6), δ 30.5 (C-7), δ 42.2 (C-8), δ 
50.2 (C-9), δ 38.6 (C-10), δ 55.5 (C-11), δ 56.9 (C-12), δ 89.5 (C-13), δ 42.3 (C-
14), δ 27.5 (C-15), δ 23.5 (C-16), δ 45.7 (C-17), δ 60.9 (C-18), δ 40.8 (C-19), δ 
38.0 (C-20), δ 31.2 (C-21), δ 32.4 (C-22), δ 105.7 (C-23), δ 16.3 (C-25), δ 20.8 (C-





4-3-13. Compound 13 
White amorphous powder; []𝐷
20 +51.4 (c 0.3, MeOH); UV λmax (MeOH) 
(log ɛ) (nm) 196 (3.15); IR (KBr) νmax (cm–1) 3392, 2966, 2934, 2866, 2359, 1688, 
1054, 1033, 1016; ESIMS m/z 495.3 [M+Na]+, 455.3 [M-H2O+H]+, 437.2 [M-
2H2O+H]+, 471.3 [M-H]-. 
 1H NMR (500 MHz, pyridine-d5, δ in ppm) : δ 5.85 (1 H, br s, H-23b), δ 
5.61 (1 H, br s, H-12), δ 5.07 (1 H, br s, OH-19), δ 4.95 (1 H, br s, H-23a), δ 4.36 
(1 H, d, J= 8.75 Hz, H-3), δ 4.05 (1 H, m, H-2), δ 3.13 (1 H, td, J= 3.9, 12.8 Hz, H-
16b), δ 3.07 (1 H, s, H-18), δ 2.07 (1 H, m, H-16a), δ 1.87 (1 H, t, J= 8.75, H-5), δ 
1.54 (1 H, m, H-20), δ 1.75 (3 H, s, H-27), δ 1.46 (3 H, s, CH3-29), δ 1.15 (3 H, s, 
CH3-26), δ 1.14 (3 H, d, J= 6.0 Hz, H-30), δ 0.85 (3 H, s, CH3-25). 
13C NMR (125 MHz, pyridine-d5, δ in ppm) : δ 48.6 (C-1), δ 74.0 (C-2), δ 
80.0 (C-3), δ 153.0 (C-4), δ 51.2 (C-5), δ 22.1 (C-6), δ 32.5 (C-7), δ 40.9 (C-8), δ 
45.7 (C-9), δ 39.3 (C-10), δ 25.5 (C-11), δ 128.6 (C-12), δ 140.7 (C-13), δ 42.8 (C-
14), δ 29.7 (C-15), δ 26.9 (C-16), δ 48.8 (C-17), δ 55.2 (C-18), δ 73.2 (C-19), δ 
42.9 (C-20), δ 27.4 (C-21), δ 39.0 (C-22), δ 105.1 (C-23), δ 15.6 (C-25), δ 17.7 (C-
26), δ 25.2 (C-27), δ 181.2 (C-28), δ 27.6 (C-29), δ 17.3 (C-30). 
 
 
4-3-14. Compound 14 
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White amorphous powder; []𝐷
20 +20.9 (c 0.3, MeOH); UV λmax (MeOH) 
(log ɛ) (nm) 194 (2.49); IR (KBr) νmax (cm–1) 3384, 2980, 2942, 1688, 1679, 1640, 
1052, 1033; ESIMS m/z 471.3 [M-H2O+H]+, 511.3 [M+Na]+, 487.3 [M-H]-. 
 1H NMR (500 MHz, pyridine-d5, δ in ppm) : δ 5.45 (1 H, t-like s, H-12), δ 
4.20 (1 H, m, H-2), δ 4.20 (1 H, m, H-23b), δ 3.71 (1 H, d, J= 10.3 Hz, H-23a), δ 
3.28 (1 H, d, J= 10.6 Hz, H-3), δ 1.18, 1.06, 1.06, 1.03, 0.97, 0.89 (each 3 H, s). 
13C NMR (125 MHz, pyridine-d5, δ in ppm) : δ 48.2 (C-1), δ 69.3 (C-2), δ 
78.7 (C-3), δ 44.1 (C-4), δ 48.7 (C-5), δ 19.0 (C-6), δ 33.4 (C-7), δ 40.3 (C-8), δ 
48.4 (C-9), δ 38.9 (C-10), δ 24.4 (C-11), δ 123.0 (C-12), δ 145.3 (C-13), δ 42.7 (C-
14), δ 28.8 (C-15), δ 24.1 (C-16), δ 47.1 (C-17), δ 42.4 (C-18), δ 46.9 (C-19), δ 
31.4 (C-20), δ 34.7 (C-21), δ 33.7 (C-22), δ 67.0 (C-23), δ 14.8 (C-24), δ 18.0 (C-
25), δ 17.8 (C-26), δ 26.6 (C-27), δ 180.7 (C-28), δ 33.7 (C-29), δ 24.2 (C-30). 
 
 
4-3-15. Compound 15 
White amorphous powder; []𝐷
20 +38.6 (c 0.3, MeOH); UV λmax (MeOH) 
(log ɛ) (nm) 196 (2.55); IR (KBr) νmax (cm–1) 3389, 2950, 2844, 2359, 2341, 1688, 
1644, 1054, 1033, 1015; ESIMS m/z 479.3 [M+Na]+, 455.3 [M-H]-. 
1H NMR (800 MHz, pyridine-d5, δ in ppm) : δ 5.86 (1 H, br s, H-23b), δ 
5.50 (1 H, br s, H-12), δ 4.95 (1 H, br s, H-23a), δ 4.36 (1 H, d, J= 8.8 Hz, H-3), δ 
4.05 (1 H, m, H-2), δ 2.64 (1 H, br d, J= 11.4 Hz , H-18), δ 1.22 (3 H, s, CH3-27), δ 
1.09 (3 H, s, CH3-26), δ 1.00 (3 H, d, J= 6.4 Hz, CH3-29), δ 0.97 (3 H, d, J= 6.4 
Hz, H-30), δ 0.83 (3 H, s, CH3-25). 
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13C NMR (200 MHz, pyridine-d5, δ in ppm) : δ 48.7 (C-1), δ 73.9 (C-2), δ 
80.0 (C-3), δ 153.0 (C-4), δ 51.1 (C-5), δ 21.9 (C-6), δ 32.4 (C-7), δ 39.9 (C-8), δ 
45.9 (C-9), δ 39.2 (C-10), δ 25.4 (C-11), δ 126.2 (C-12), δ 140.0 (C-13), δ 43.2 (C-
14), δ 29.0 (C-15), δ 25.1 (C-16), δ 48.5 (C-17), δ 54.1 (C-18), δ 39.9 (C-19), δ 
40.5 (C-20), δ 31.5 (C-21), δ 37.9 (C-22), δ 105.1 (C-23), δ 15.7 (C-25), δ 17.9 (C-
26), δ 24.3 (C-27), δ 180.4 (C-28), δ 18.0 (C-29), δ 21.9 (C-30). 
 
 
4-3-16. Compound 16 
Yellowish amorphous powder; []𝐷
20 -4.0 (c 0.3, MeOH); UV λmax (MeOH) 
(log ɛ) (nm) 200 (3.25) 340 (3.13); IR (KBr) νmax (cm–1) 3445, 3419, 2936, 2359, 
1628, 1611, 1564, 1350, 1167, 991, 970; ESIMS m/z 299.1 [M+H]+, 297.1 [M-H]-. 
1H NMR (800 MHz, chloroform-d, δ in ppm) : δ 13.63 (1 H, br s, OH-4’), δ 
8.00 (1 H, d, J= 15.6 Hz, H-α), δ 7.85 (1 H, d, J= 15.7 Hz, H-β), δ 7.65 (2 H, dd, 
J= 1.2, 7.9 Hz, H-2 and H-6), δ 7.41 (3 H, m, H-3, H-4 and H-5), δ 5.56 (1 H, br s, 
OH-4’), δ 3.66 (3 H, s, OCH3-5), δ 2.16 (3 H, s, CH3-5’), δ 2.14 (3 H, s, CH3-3’). 
13C NMR (200 MHz, chloroform-d, δ in ppm) : δ 135.5 (C-1), δ 128.5 (C-2), 
δ 129.1 (C-3), δ 130.4 (C-4), δ 129.1 (C-5), δ 128.5 (C-6), δ 126.8 (C-α), δ 143.1 
(C-β), δ 193.5 (C=O), δ 109.2 (C-1’), δ 159.0 (C-2’), δ 109.1 (C-3’), δ 159.4 (C-






4-3-17. Compound 17 
Brownish gum; []𝐷
20 +6.6 (c 0.3, MeOH); UV λmax (MeOH) (log ɛ) (nm) 
198 (3.29) 216 (3.21) 296 (3.17); IR (KBr) νmax (cm–1) 3398, 2981, 2952, 2842, 
1658, 1639, 1451, 1116, 1018; ESIMS m/z 285.1 [M+H]+, 283.2 [M-H]-. 
1H NMR (800 MHz, DMSO-d6, δ in ppm) : δ 12.36 (1 H, br s, OH-5), δ 7.51 
(2 H, d, J= 7.4 Hz, H-2’ and H-6’), δ 7.43 (2 H, t, J= 7.4 Hz, H-3’ and H-5’), δ 
7.37 (1 H, t, J= 7.4 Hz, H-4’), δ 5.55 (1 H, dd, J= 3.1, 12.2 Hz, H-2), δ 3.18 (1 H, 
dd, J= 12.3, 17.0 Hz, H-3α), δ 2.84 (1 H, dd, J= 3.3, 17.0 Hz, H-3β), δ 1.97 (3 H, s, 
CH3-6), δ 1.96 (3 H, s, CH3-8). 
13C NMR (200 MHz, DMSO-d6, δ in ppm) : δ 77.9 (C-2), δ 42.2 (C-3), δ 
196.6 (C-4), δ 101.8 (C-4a), δ 158.5 (C-5), δ 103.4 (C-6), δ 162.6 (C-7) , δ 102.7 
(C-8), δ 157.2 (C-8a), δ 139.2 (C-1’), δ 126.3 (C-2’), δ 128.6 (C-3’), δ 128.4 (C-
4’), δ 128.6 (C-5’), δ 126.3 (C-6’), δ 8.3 (CH3-6), δ 7.7 (CH3-8).  
 
 
4-3-18. Compound 18 
Brownish gum; []𝐷
20 -2.9 (c 0.3, MeOH); UV λmax (MeOH) (log ɛ) (nm) 192 
(3.05) 218 (2.91) 284 (2.70); IR (KBr) νmax (cm–1) 3398, 2954, 2843, 1648, 1535, 
1109, 1017; ESIMS m/z 299.2 [M+H]+, 297.2 [M-H]-. 
1H NMR (400 MHz, chloroform-d, δ in ppm) : δ 7.46 (2 H, d, J= 7.2 Hz, H-
2’ and H-6’), δ 7.42 (1 H, t, J= 7.4 Hz, H-3’ and H-5’), δ 7.37 (1 H, t, J= 7.0 Hz, 
H-4’), δ 5.42 (1 H, dd, J= 2.5, 12.8 Hz, H-2), δ 3.81 (3 H, s, OCH3-5), δ 2.97 (1 H, 
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dd, J= 13.0, 16.7 Hz, H-3α), δ 2.84 (1 H, dd, J= 2.8, 16.6 Hz, H-3β), δ 2.13 (3 H, s, 
CH3-6), δ 2.13 (3 H, s, CH3-8). 
13C NMR (100 MHz, chloroform-d, δ in ppm) : δ 78.6 (C-2), δ 45.8 (C-3), δ 
189.9 (C-4), δ 109.2 (C-4a), δ 157.8 (C-5), δ 111.4 (C-6), δ 159.0 (C-7) , δ 107.1 
(C-8), δ 159.7 (C-8a), δ 139.4 (C-1’), δ 126.0 (C-2’), δ 128.9 (C-3’), δ 128.6 (C-
4’), δ 128.9 (C-5’), δ 126.0 (C-6’), δ 8.0 (CH3-6) , δ 8.3 (CH3-8), δ 61.4 (OCH3-5).  
 
 
4-3-19. Compound 19 
White amorphous powder; []𝐷
20 +26.2 (c 0.3, MeOH); UV λmax (MeOH) 
(log ɛ) (nm) 192 (2.86) 210 (2.80) 224 (2.73) 310 (3.02); IR (KBr) νmax (cm–1) 
3391, 2972, 2950, 2844, 1688, 1640, 1516, 1452, 1050, 1033, 1016; ESIMS m/z 
619.3 [M+H]+, 617.4 [M-H]-. 
1H NMR (800 MHz, pyridine-d5, δ in ppm) : δ 8.04 (1 H, d, J= 15.8 Hz, H-
3’), δ 7.58 (2 H, d, J= 8.6 Hz, H-5’ and H-9’), δ 7.19 (2 H, d, J= 8.6 Hz, H-6’ and 
H-8’), δ 6.72 (1 H, d, J= 15.9 Hz, H-2’), δ 5.49 (1 H, t, J= 3.2 Hz, H-12), δ 5.28 (1 
H, d, J= 9.4 Hz, H-3), δ 4.33 (1 H, m, H-2), δ 3.33 (1 H, dd, J= 3.7, 14.1 Hz, H-
18), δ 1.29, 1.08, 1.08, 1.06, 1.03, 1.02, 0.98 (each 3 H, s). 
13C NMR (200 MHz, pyridine-d5, δ in ppm) : δ 48.5 (C-1), δ 66.9 (C-2), δ 
85.5 (C-3), δ 40.3 (C-4), δ 56.0 (C-5), δ 19.1 (C-6), δ 33.7 (C-7), δ 40.3 (C-8), δ 
48.9 (C-9), δ 38.9 (C-10), δ 24.4 (C-11), δ 122.9 (C-12), δ 145.3 (C-13), δ 42.7 (C-
14), δ 28.8 (C-15), δ 24.2 (C-16), δ 47.1 (C-17), δ 42.4 (C-18), δ 46.9 (C-19), δ 
31.4 (C-20), δ 34.7 (C-21), δ 33.7 (C-22), δ 29.5 (C-23), δ 17.2 (C-24), δ 17.9 (C-
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25), δ 18.7 (C-26), δ 26.7 (C-27), δ 180.7 (C-28), δ 33.5 (C-29) , δ 24.2 (C-30), δ 
168.4 (C-1’), δ 116.6 (C-2’), δ 145.5 (C-3’), δ 126.8 (C-4’), δ 131.1 (C-5’), δ 117.3 
(C-6’), δ 161.8 (C-7’), δ 117.3 (C-8’), δ 131.1 (C 
 
 
4-3-20. Compound 20 
White amorphous powder; []𝐷
20 +20.9 (c 0.3, MeOH); UV λmax (MeOH) 
(log ɛ) (nm) 192 (2.79) 304 (2.50); IR (KBr) νmax (cm–1) 3394, 2981, 2949, 2844, 
1705, 1658, 1646, 1053, 1033, 1014; ESIMS m/z 619.3 [M+H]+, 617.4 [M-H]-. 
1H NMR (600 MHz, pyridine-d5, δ in ppm) : δ 8.15 (2 H, d, J= 8.6 Hz, H-5’ 
and H-9’), δ 7.17 (2 H, d, J= 8.6 Hz, H-6’ and H-8’), δ 6.95 (1 H, d, J= 12.9 Hz, H-
3’), δ 6.14 (1 H, d, J= 12.8 Hz, H-2’), δ 5.47 (1 H, t, J= 3.1 Hz, H-12), δ 5.21 (1 H, 
d, J= 9.8 Hz, H-3), δ 4.26 (1 H, m, H-2), δ 3.31 (1 H, dd, J= 4.3, 13.7 Hz, H-18), δ 
1.25, 1.06, 1.03, 1.01, 0.99, 0.98, 0.97 (each 3 H, s). 
13C NMR (150 MHz, pyridine-d5, δ in ppm) : δ 48.5 (C-1), δ 66.8 (C-2), δ 
85.4 (C-3), δ 40.2 (C-4), δ 56.0 (C-5), δ 19.1 (C-6), δ 33.7 (C-7), δ 40.1 (C-8), δ 
48.9 (C-9), δ 38.9 (C-10), δ 24.4 (C-11), δ 122.7 (C-12), δ 143.2 (C-13), δ 42.7 (C-
14), δ 28.8 (C-15), δ 24.3 (C-16), δ 47.2 (C-17), δ 42.4 (C-18), δ 46.9 (C-19), δ 
31.4 (C-20), δ 34.7 (C-21), δ 33.7 (C-22), δ 29.4 (C-23), δ 17.2 (C-24), δ 17.9 (C-
25), δ 18.6 (C-26), δ 26.6 (C-27), δ 180.7 (C-28), δ 33.5 (C-29) , δ 24.2 (C-30), δ 
167.7 (C-1’), δ 117.6 (C-2’), δ 144.0 (C-3’), δ 127.2 (C-4’), δ 134.2 (C-5’), δ 116.4 




Table 1. 1H (600 MHz) and 13C (150 MHz) NMR data of compounds 1-3.   
no. 
1 2 3 
δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) δC 
1 1.73 d (13.1) 
0.99 m 
39.8 2.62 dd (5.0, 
12.7) 
1.72 m 
48.2 1.75 m 
1.08 m 
39.6 
2 1.86 m 
1.80 m 
28.8 4.13 m 73.7 1.92 m 
1.86 m 
28.3 
3 3.27 dd (4.7, 
11.3) 
78.3 4.38 d (8.8) 79.9 4.05 dd (4.0, 
11.3) 
74.0 
4  39.9  151.9  43.3 
5 0.88 m 56.5 50.4 br d (12.2) 50.4 1.54 m 49.6 
6 1.62 m 
1.42 m 
19.3 1.64 m 
1.50 m 
21.1 1.68 m 
1.45 m 
19.2 
7 3.01 m 
1.93 m 
38.8 1.28 m 
1.06 m 
30.5 2.15 m 
1.87 m 
38.6 
8  41.3  42.3  41.3 
9 1.93 m 52.2 1.90 br s 50.1 2.03 m 52.2 
10  38.3  38.7  38.2 
11 1.57 m 
1.31 m 
21.7 3.32 dd (2.4, 3.1) 55.3 1.60 m 
1.35 m 
21.7 
12 2.79 m 
1.89 m 
28.1 3.07 d (3.7) 56.8 2.70 m 
2.01 m 
27.4 
13 2.79 m 40.7  89.7 2.71 m 40.7 
14  60.3  42.2  60.4 
15 2.50 d (13.4)  
1.57 m 
29.1 1.73 m 
1.03 m 
27.5 2.47 d (13.4)  
1.56 m 
29.0 
16 2.68 m 
1.93 m 
35.3 2.31 m 
1.42 m 
23.5 2.65 m 
1.88 m 
35.4 
17  57.3  45.7  57.3 
18 2.33 t (11.1) 53.0 1.88 m 61.6 2.13 m 52.9 
19 3.53 td (4.7, 
11.3) 
44.2 2.71 m 36.6 3.51 td (4.2, 10.9) 48.2 
20  156.5  152.4  151.2 
21 2.20 m 
1.63 m 
33.0 2.23 m 
2.29 m 
32.4 2.03 m 
1.46 m 
31.3 
22 2.01 m 
1.57 m 
37.5 1.96 dt (3.1, 
12.9) 
1.62 m 
33.8 2.02 m 
1.45 m 
37.7 
23 1.08 s 29.0 5.89 br s  
4.99 br s 
105.7 4.10 d (10.3) 
3.59 d (10.3) 
68.5 
24 1.01 s 17.0   1.06 s 13.5 
25 0.91 s 17.5 0.91 s 16.3 0.99 s 17.8 
26 1.18 s 17.9 1.17 s 20.7 1.20 s 17.9 
27  178.8 1.18 s 16.7  178.8 
28  177.3  178.6  177.4 
29 5.61 br s  
5.38 br s 
107.3 1.45 d (6.3) 16.9 5.04 br s 
4.81 br s 
111.0 
30 4.73 d (15.0) 
4.56 d (15.0) 
64.7 4.87 br s 
4.81 br s 
108.7 1.89 s 19.7 
OCH3 3.77 s 51.9   3.77 s 52.0 
 
pyridine-d5 used as solvent. 




5. Bioassay procedures 
5-1. PTP1B enzyme assay 
PTP1B inhibition assay procedure was followed by previously described literature 
(Bruke et al., 1996). Briefly, ursolic acid, a famous dominant PTP1B inhibitor, was 
operated as a positive control. the enzyme activity was measured using 0.05 – 0.1 µg 
of PTP1B, 4 mM p-NPP as a substrate in buffer containing 1 mM DTT, 0.1 M NaCl, 
1 mM EDTA, and 50 mM citrate (pH 6.0) with or without the isolates to make the 
final volume 100 μL in 96-well plates. After the reaction mixture was incubated at 
37 °C for 30 min, 10 M NaOH was added to quench the reaction. The enzyme activity 
was measured by the amount of produced p-nitrophenol using the absorbance at 405 
nm by VersaMax. The nonenzymatic hydrolysis of 4 mM p-NPP was corrected by 
measuring the control, which did not contain PTP1B enzyme. 
 
5-2. Statistical analysis 
The results are presented as the mean ± SD of duplicate experiments. 
Characteristics were compared between groups, and their differences were tested by 
the unpaired student’s t-test. All statistical analyses were performed using SAS 
version 9.4.0 (SAS Institute, Cary, NC, USA). A p-value < 0.05 was considered to 





III. Results and Discussion 
1. Structural elucidation of isolated compounds (1-20) 
1-1. Compound 1 
Compound 1 was obtained as brownish gum. Its molecular formula was 
assigned as C31H48O6 by [M-H]- ion peak at m/z 515.3379 (calcd. 515.3378) by HR-
ESIMS. The IR spectrum indicated the presence of hydroxyl (3364 cm–1), ester (1706 
and 1219 cm–1), and carboxylic acid (2946 and 1697 cm–1) functionalities. The 1H 
NMR spectrum (Table 1) revealed two olefinic protons at H 5.61 (1H, br s) and 5.38 
(1H, br s), one methoxy group at H 3.77 (3H, s), one oxygenated methine proton at 
H 3.27 (1H, dd, J = 4.7, 11.3 Hz). Also, there are signals of two hydroxyl methylene 
protons at H 4.73 and 4.56 (2H, d, J = 15.0 Hz) and four methyl singlets at H 1.18, 
1.08, 1.01, and 0.91 (3H, s). The 13C NMR spectrum showed 31 signals, including 
two carboxylic groups in the downfield region at C 178.8 and 177.3, one exocyclic 
methylene at C 107.3 and 156.5, one oxygenated carbon at C 78.3, a methoxy group 
at C 51.9, a hydroxyl methylene carbon at C 64.7, and four methyl groups at C 
29.0, 17.0, 17.5, and 17.9. From the above signals, one more carbon was added to a 
common triterpenoid. The NMR data of compound 1 was very similar to that of 
Melaleucic acid 28-O-methyl ester (Kaneta et al., 2017). The major difference 
between compound 1 and Melaleucic acid 28-O-methyl ester was the presence of a 
hydroxyl methylene (C 64.7) in lieu of a methyl (C 19.0) in the former at C-30. The 
signals (C-30) at H 4.73 and 4.56 were recognized as the attachment of a hydroxyl 
group by the HSQC. HMBC correlation confirmed the interactions of the hydroxyl 
methylene protons (C-30) at H 4.73 and 4.56 to the double bond moiety (C-20 and 
C-29) at C 156.5 and 107.3, C-19 at C 44.2 attached to a pentacyclic ring. Also, the 
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correlations from H-22 at H 2.01 and 1.57, and H-16 at H 1.93 to methyl ester 
carbon of C-28 (C 177.3), and from H-13 (H 2.79) and H-15 (H 1.57) to C-27 (C 
178.8) finally established the positions of methyl ester (C-28) and carboxylic acid 
(C-27). NOESY correlations were observed for H-3α/CH3-23, H-3α/H-5α, H-5α/H-
9α, CH3-24/CH3-25, CH3-25/CH3-26, CH3-26/H-13β, and H-13β/H-19β. Therefore, 
the chemical structure of compound 1 was completely determined as cleistocalyxic 









Figure 2. 1H and 13C NMR spectra of compound 1  
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Figure 4. NOESY spectrum of compound 1 
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1-2. Compound 2 
Compound 2, a white amorphous powder, was determined to have a molecular 
formula of C29H40O5 by HR-ESIMS (m/z 513.2856 [M+HCOO]-, calcd. 513.2858). 
The IR spectrum indicated the presence of hydroxyl groups (broad 3365 cm–1) and 
ester group (1775 and 1149 cm–1). The 1H NMR spectrum of compound 2 (Table 1) 
revealed two pairs of exomethylene protons, H 5.89 (1H, br s, H-23) and 4.99 (1H, 
br s, H-23), and H 4.87 (1H, br s, H-30) and 4.81 (1H, br s, H-30), and four 
oxygenated protons at H 4.38 (1H, d, J = 8.8 Hz, H-3), 4.13 (1H, m, H-2), 3.32 (1H, 
dd, J = 2.4, 3.1 Hz, H-11), and 3.07 (1H, d, J = 3.7 Hz, H-12). Three singlet signals 
were shown for methyl groups at H 0.91 (H-25), 1.17 (H-26) and 1.18 (H-27), and 
one doublet signal was detected at H 1.45 (3H, d, J = 6.3 Hz, H-29). The 13C NMR 
spectrum of compound 2 was observed 29 signals represented as a nor-type 
triterpenoid. There are also signals of one carboxylic group at C 178.6, two 
exocyclic methylenes at C 152.4, 151.9, 108.7 and 105.7, five oxygenated carbons 
at C 89.7, 79.9, 73.7, 56.8 and 55.3, and four methyl groups at C 20.7, 16.9, 16.7, 
and 16.3. The NMR data of compound 2 were very similar to those of ulmoidol 
isolated from Ilex kudincha (Nishimura et al., 1999). The major difference between 
compound 2 and ulmoidol was replaced a methyl group C-30 (C 19.5) to a double 
bond (C 108.6 and 151.3). The HMBC correlation analysis supported that the 
structure has ulmoidol moiety. The signal H 2.71 at H-19 had correlations with C-
29 (C 16.9), C-30 (C 108.7), C-18 (C 61.6), and C-20 (C 152.4). The interactions 
of a remarkable proton signal H 1.88 at H-18 had many correlations such as C-28 
(C 178.6), C-29 (C 16.9), C-17 (C 45.7), C-13 (C 89.7), and C-12 (C 56.8) 
because of its position on the structure (Figure 5). It is supported to have the presence 
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of lactone ring. HMBC correlation from a methyl group H 1.18 (CH3-27) to 
quaternary carbon C 89.7 (C-13) supported the formation of lactone moiety 
connected to C-13, C-17, and C-28. Lastly, the correlations of H 4.38 at H-3 to C-2 
(C 73.7), C-4 (C 151.9) and C-23 (C 105.7) made the position of 23-nor-
triterpenoid. NOESY correlations was performed to confirm the stereochemistry of 
the structure with the correlations H-3α/H-5α, H-5α/H-9α, H-9α/CH3-27, CH3-27/H-
19α, H-2β/CH3-25, CH3-25/CH3-26, CH3-25/H-11β, H-11β/H-12β, CH3-26/H-12β, 
H-12β/H-18β, and H-18β/CH3-29. Therefore, the compound 2 was firstly proposed 












































































Figure 7. NOESY spectrum of compound 2 
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1-3. Compound 3 
Compound 3 was obtained as white amorphous powder. Its molecular formula 
was assigned as C31H48O6 from the HRESIMS data (m/z 515.3381 [M-H]-, calcd. 
515.3378). In the IR spectrum, absorption bands showed the presence of hydroxyl 
(3245 cm-1), ester (1718 and 1212 cm-1), and carboxyl (2934 and 1680 cm-1) groups. 
The 1H NMR spectrum and 13C NMR spectra (Table 1) were closely identical to 
those of 1 with the only difference being the change of a hydroxyl group position 
from H 4.73 and 4.56 at the C-30 in compound 1 to H 4.10 and 3.59 at the C-23 in 
compound 3. Based on HSQC, two correlations from C 68.5 at C-23 to H 4.10 and 
3.59 at H-23α and H-23β were assumed to have a hydroxyl group at C-23. HMBC 
signals of H-23α and H-23β clearly set the position as the correlations were seen at 
C 74.0 at C-3, C 43.3 at C-4, C 49.6 at C-5, and C 13.5 at C-24. The correlations 
from H-22 at H 2.02 and 1.45, and H-16 at H 1.88 to the methyl ester carbon of C-
28 (C 177.3) were also confirmed where its location is. Other correlations from H-
13 (H 2.71) to H-15 (H 1.56) and C-27 (C 178.8) finally established the position 
of carboxylic acid (C-27). NOESY correlations were observed for H-3α/CH3-23, H-
3α/H-5α, H-5α/H-9α, CH3-24/CH3-25, CH3-25/CH3-26, CH3-26/H-13β, and H-
13β/H-19β to determine the configuration of 3. It is consistent with 1 by 
interpretation of its NOESY spectrum. Therefore, the structure of 3 as a new 
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1-4. Compound 4 
Compound 4 was isolated as white amorphous powder with []𝐷
20  = +5.0 (c, 
0.3, MeOH). The IR spectrum showed the presence of hydroxyl (3388 cm-1), ester 
(1704 and 1165 cm-1), and carboxyl (2966 and 1680 cm-1) groups. 1H and 13C NMR 
data of 4 intended the structure as an Melaleucic 28-methyl ester, indicating the 
presence of five methyl groups at H 1.08 (CH3-23), 1.01 (CH3-24), 0.92 (CH3-25), 
1.18 (CH3-26), and 1.90 (CH3-30). Here, H 1.90 is a notable methyl group next to a 
double bond, C-20 and C-29 in a betulinic moiety. Also, two olefinic protons at H 
5.05 (br s, H-29) and H 4.83 (br s, H-29) with two olefinic carbons C 151.1 (C-20) 
and C 111.0 (C-29) and two carboxylic groups at C 178.8 (C-27) and C 177.4 (C-
28) were confirmed as closely consistent the compound 1 without only one hydroxyl 
group.  
Based on the above deductions and comparing spectrums with reference 
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1-5. Compound 5 
Compound 5 was purified as white amorphous powder, with the  []𝐷
20 +14.4 
(c 0.3, MeOH). IR spectrum represented the existence of hydroxyl (3335 cm-1) and 
carboxyl (2928 and 1687 cm-1) groups. 1H and 13C NMR spectra showed the signals 
as six methyl groups, H 1.09 (CH3-24), 1.14 (CH3-25), 1.11 (CH3-26), 1.43 (CH3-
27), 1.67 (CH3-29), and 1.13 (CH3-30), as well as a hydroxymethyl group at H 3.73 
and 4.21 (C-23, d, J= 10.5). One carboxylic acid (C 181.2) and two olefinic carbons 
(c 128.5 and 140.5) also detected, and four oxygenated carbons, at C 69.4 (C-2), 
78.8 (C-3), 67.1 (C-23), and 73.2 (C-19), supported to construct what the structure 
it is. One of the proton, C 3.06 (s, H-18) recognized as a singlet where no protons 
presented right next to its position.   
With rational analysis of the above information, 1D NMR data were consistent 
to those of known compound 19α-hydroxyasiatic acid (Hiroshi et al., 2007). This 
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1-6. Compound 6 
Compound 6, white amorphous powder, was yielded. The optical rotation 
values was [𝛼]𝐷
20 -4.3 (c 0.3, MeOH). The IR spectrum revealed the hydroxyl (3398 
cm-1) and carbonyl (1681 cm-1) functionalities in the structure. The 1D NMR spectra 
indicated the presence of one exocyclic double bond, H-29 (δH 4.96 and 4.79), C-20 
(δC 151.3), and C-29 (δC 109.9).  Six methyl groups were in this structure, and one 
of them noticeably showed an unexpected deshield methyl peak at δH 1.81 (s, H-30) 
because of its location right next to double bond such as compound 4.     
Based on the above notable peaks, the NMR data of 6 were identical to those of 
previously reported compound betulinic acid (Kang et al., 2016). ESI-MS data also 
confirmed the structure of 6 by the ion peaks at m/z 439.3 [M-H2O+H]+ and 455.4 
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1-7. Compound 7 
Compound 7 was isolated as white amorphous powder with [𝛼]𝐷
20 +43.6 (c 0.3, 
MeOH). The IR spectral analysis showed the presence of hydroxyl (3393 cm-1) and 
carboxylic acid (1688 and 1460 cm-1) groups. The ion peaks at m/z 439.3 [M-
H2O+H]+ and 455.4 [M-H]- offered the molecular weight of 456 on ESI-MS. From 
1D NMR, there is one oxygenated proton δH 3.21 at H-3 and seven singlet methyls 
as common triterpenoid moiety. An olefinic proton signal of δH 5.27 (t-like s) at H-
12 usually indicated to endocyclic double bond. From the carbon signals, δC 143.8 
(C-13) and δC 122.8 (C-12) supported that the structure has a double bond inside of 
the ring system. There is also one carboxylic acid δC 183.6 (C-28). All of them 
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1-8. Compound 8 
Compound 8 was obtained as white amorphous powder. Its specific rotation 
was measured, [𝛼]𝐷
20 +9.3 (c 0.3, MeOH). IR spectrum showed the absorption bands 
at 3366, 2937, 1748, and 1049 cm-1 referred as hydroxyls and ester functionalities. 
The 1H and 13C NMR showed the presence of lactone ring because of the carbon 
signal, δC 92.0 at C-13, usually shared an ester bridge, δC 180.2 at C-28. The meaning 
of three oxygenated protons, δH 4.20 at H-12, δH 4.13 at H-2, and δH 3.38 at H-3,was 
substitutions of three hydroxyl groups. Seven methyl groups for δH 1.29, 1.12, 1.02, 
1.35, 1.61, 0.82, and 0.92 also signified a common skeleton of triterpenoid. 
Spectral data of 8 were observed to be consistent with those of known 
compound, (2α, 3β, 12α) 2, 3, 12-Trihydroxy-olean-28-oic acid 28, 13-lactone 
(Siewert et al., 2014). ESI-MS data further supported to the structure with m/z 489.3 









Figure 15. 1H and 13C NMR spectra of compound 8 
 
 
































1-9. Compound 9 
Compound 9, white amorphous powder, had the specific rotation of [𝛼]𝐷
20 +32.3 
(c 0.3, MeOH). The IR absorption band at 3392 cm-1 indicated the presence of 
hydroxyl group while a carboxylic acid band showed at 1704 cm-1. The 1H NMR and 
13C NMR revealed it is really similar to the compound 7 without only one hydroxyl 
substitution at δH 4.12 (H-2) and δC 69.2 (C-2).  
All of the above information has led to the compound 9 was structurally 
deduced as maslinic acid (Taniguchi et al., 2002). Futhermore, ESI-MS spectra, 
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1-10. Compound 10 
Compound 10 was isolated as white amorphous powder with [𝛼]𝐷
20 -5.8 (c 0.3, 
MeOH). The IR spectral analysis showed the presence of hydroxyls (3384 cm-1) and 
one carboxylic acid (1705 and 1375 cm-1) in the structure. With the 1D NMR data 
of 10 exhibited the similar patterns to compound 6 except for one hydroxyl group 
attachment on C-2 (δH 4.08 and δC 69.1). The 1H and 13C NMR data were identical to 
those of previously reported compound, alphitolic acid (Kang et al., 2016). This was 
further supported by the co-appearance of protonated and deprotonated peaks on 
ESI-MS spectrums (m/z 495.3 [M+Na]+ and 471.3 [M-H]-, verifying to molecular 
weight as 472). 
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1-11. Compound 11 
Compound 11, white amorphous powder, was obtained, and the optical rotation 
value was calculated [𝛼]𝐷
20 +53.6 (c 0.3, MeOH). The IR spectral analysis showed 
the existence of hydroxyl group (3335 cm-1). This compound is closely identical to 
the 1H and 13C NMR spectra of compound 7. It displayed the signals of δH 3.56 and 
3.21 (d, 11.0) at H-28 and δC 69.9 at C-28 which meant by absence of carboxylic 
acid and appearance of hydroxymethyl group. Based on the above spectral 
observation and comparison to the reference, compound 11 was structurally 











































1-12. Compound 12 
Compound 12 was purified as white amorphous powder with the optical rotation 
[𝛼]𝐷
20 +54.0 (c 0.3, MeOH). The IR spectrum showed bands at 3388 cm-1 (hydroxyl) 
and 2870 and 1772 cm-1 (carbonyl). The protonated peak [M+H]+ at m/z 471.3 and 
deprotonated peak [M+HCOO]- at m/z 515.4 indicated the molecular weight as 470 
with the molecular formula, C29H42O5. The 1D NMR spectra was closely consistent 
to those of compound 2 with disappearing one exocyclic double bond δH 0.92 (3H, 
d, J= 6.5 Hz) and δC 20.2 at C-30 position. All NMR spectra were consistent with 
previously reported compound, ulmoidol (Nishimura et al., 1999). Therefore, its 
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1-13. Compound 13 
Compound 13 was yielded as white amorphous powder with [𝛼]𝐷
20 +51.4 (c 0.3, 
MeOH). The IR spectrum showed absorption bands at 3392 and 1688 cm-1, 
representing to hydroxyl and carbonyl groups, respectively. 1H NMR data displayed 
the characteristics of two double bonds (δH 4.95, 5.85, and 5.61), two hydroxyl 
groups (δH 4.05 and 4.36) and five methyls (δH 0.85, 1.15, 1.75, 1.46, and 1.14). The 
13C NMR supported all of these functionalities in the structure; however, one more 
oxygenated carbon δC 73.2 at C-19 was showed. Based on the above spectral 
dedeuction and comparison to the data of reference, compound 13 was fully 
elucidated as 2α,3β,19α-Trihydroxy-24-norurs- 4(23),12-dien-28-oic acid (Jang et 
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1-14. Compound 14 
Compound 14 as white amorphous powder has the optical rotation value of 
[𝛼]𝐷
20 +20.9 (c 0.3, MeOH). IR spectrum showed 3384 cm-1 as the hydroxyl and 1688 
cm-1 as the carboxyl. The 1D NMR patterns of 14 were observed to be similar to 
those of 9, indicating one double bond, one carboxylic acid, and two hydroxyl groups. 
However, it is suggested that 14 possessed the hydroxymethyl group through the 
peaks of H-23 (δH 3.71 and 4.20) and C-23 (δC 67.0) because of comparing the 
chemical shifts difference with compound 9. As a result, the structure of 14 was 
characterized as arjunolic acid (Li et al., 2009) by comparison of the physical and 
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(d, J= 10.2) 
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1-15. Compound 15 
Compound 15 was gained as white amorphous powder. The optical rotation 
was [𝛼]𝐷
20 +38.6 (c 0.3, MeOH). The absorption bands at 3389 cm-1 and 1688 cm-1 
in IR spectrum represented the existence of hydroxyl group and carbonyl function, 
respectively. The 1H NMR data of 15 showed the diagnostic resonances 
corresponding to a nor-triterpenoid type, including 29 total carbon peaks. Two 
oxygenated protons, δH 4.05 at H-2 and δH 4.36 at H-3, two olefinic double bonds, 
δH 5.50 at H-12 and δH 4.95 and 5.86 at H-23, and five methyl groups, δH 0.83, 1.09, 
1.22, 1.00 and 0.97. The 13C NMR data supported those evidence of two oxygenated 
carbons, δC 73.9 at C-2 and 80.0 at C-3, two double bond carbons, δC 153.0 at C-4, 
δC 105.1 at C-23, δC 126.2 at C-12, δC 140.0 at C-13, and five methyl groups for δC 
15.7, 17.9, 24.3, 18.0, and 21.9. Therefore, the deduction of all the NMR data could 
be established the compound 15 as Ilekudinol B by comparison of reported literature 
(Nishimura et al., 1999). ESI-MS data also assisted to confirm the structure (m/z 
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1-16. Compound 16 
Compound 16 was obtained as yellowish amorphous powder form. The optical 
rotation value is -4.0 at 20 degrees Celsius. The IR spectrum showed the presence of 
two hydroxyl groups at 3445 and 3419 cm-1 and a ketone at 1628 cm-1. 
The 1H NMR spectra of 16 showed a benzene moiety for δH 7.62 and 7.41 with 
5 protons, a double bond for δH 7.85 (d, J= 15.7) and δH 8.00 (d, J= 15.6), one 
methoxy at δH 3.66 (s), and two methyl groups for δH 2.16 (s) and 2.14 (s). The 13C 
NMR also supported those above functionalities with showing one more functional 
group, ketone at δC 193.5. With a logically deduction by comparing spectral data, 
compound 16 was fully elucidated as 2',4'-dihydroxy-6′-methoxy-3',5'-
dimethylchalcone by literature data (Salem et al., 2005). This was further supported 
by the co-appearance of protonated and deprotonated peaks on ESI-MS spectrums 
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1-17. Compound 17 
Compound 17, a brownish gum, possessed a dimethyl flavanone skeleton where 
the characteristic proton signals existed a benzene ring (δH 7.51, 7.43, and 7.37), a 
ketone group (δC 196.6), two methyl groups (δH 1.97 and 1.96), and a hydroxyl group 
5-OH (δH 12.36) affected by hydrogen bond interaction with ketone. This skeleton is 
also reported as one of the major constituents in this plant. Noticeably, all of the NMR 
data led to deduce the structure as Demethoxymatteucinol by previously reported 
paper (Basnet et al., 1993). The ESI-MS data showed the protonated peak [M+H]+ at 
m/z 285 and the deprotonated peak [M-H]- at m/z 283, corresponding to the molecular 
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1-18. Compound 18 
Compound 18 was purified as brownish gum with the optical rotation, []𝐷
20 -
2.9 (c 0.3, MeOH). The IR peaks at 3398 and 1648 cm-1 indicated the existence of 
hydroxyl and carbonyl functionalities. By the logical interpretation of 1H and 13C 
NMR, compound 18 was closely identical to those of compound 17 without only the 
disappearance of hydroxyl group peak at 5-OH in 17, and a methoxy peak is formed 
at δH 3.81 (s). The reliable assumption could be appeared 5-OCH3. By comparing the 
NMR data to previous paper, compound 18 is structurally determined as 7-hydroxy-
5-methoxy-6,8-dimethylflavanone (Peralta et al., 2014). The ESI-MS analysis also 














Figure 25. 1H and 13C NMR spectra of compound 18 
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1-19. Compound 19 
Compound 19 was obtained under white amorphous powder with []𝐷
20 +26.2 
(c 0.3, MeOH). From the IR spectrum, the existence of hydroxyl (3391 cm-1) and 
carbonyl (1688 cm-1) functionalities were observed. Compound 19 similarly shared 
NMR patterns to those of 9 about the signals, δH 5.49 (1H, t, J= 3.2 Hz), δH 3.42 (1H, 
d, J= 9.3 Hz), and δH 4.12 (1H, td, J= 4.2, 11.0 Hz). However, the changes between 
two oxygenated protons, from δH 3.42 in 9 to δH 5.28 in 19, led to determine the 
compound attached a functional group on C-3 position. From the 13C NMR, δC 168.4, 
116.6, 145.5, 126.8, 131.1, 117.3, 161.8, 117.3, and 131.1 recognized as the moiety 
of –O-(E)-p-coumaroyl by the reported paper (Liao et al., 2014). As a result, 3–O-
(E)-p-coumaroyl maslinic acid structurally determined. The protonated peak [M+H]+ 
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1-20. Compound 20 
Compound 20 was isolated as white amorphous powder, with []𝐷
20 +20.9 (c 
0.3, MeOH). The IR spectrum showed strong absorption bands at 3394 and 1705 cm-
1, indicating the presence of hydroxyl and ketone groups. Compound 20 is 
approximately equal to compound 19, but difference is the only characteristics of a 
coumaroyl configuration. It is represented trans to cis form from the chemical shifts 
of δH 6.14 (1H, d, J= 12.8 Hz), 6.95 (1H, d, J= 12.9 Hz), 8.15 (2H, d, J= 8.6 Hz), 
and 7.17 (2H, d, J= 8.6 Hz). Based on the comparing to literature values, the 
compound is proposed as 3–O-(Z)-p-coumaroyl maslinic acid (Liao et al., 2014). 
The protonated peak [M+H]+ at m/z 619.3 and deprotonated peak [M-H]- at m/z 617.4 
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Figure 28. Structures of compounds isolated from C. operculatus leaves 
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2. Relative mass defects (RMDs) analysis. 
 RMD analysis was performed to isolate target compounds. First, web-
databased library of compounds from leaf extracts of C. operculatus was built by 
Scifinder. Next, molecular weights were recalculated using Matlab’s in silico 
program to acquire better accuracy to four decimal places. RMD values were 
calculated by dividing the mass defect by the measured monoisotopic mass and 
multiplying it by 106 to be expressed in ppm. After the processing of RMD 
calculations, the subsequent graphs (See Figure 29) could be obtained. The graphs 
clearly showed the division of specific metabolite classes in the plant. Among the 
classes, the fractionations containing potential PTP1B inhibitors were traced to be 
the n-BuOH-soluble fraction with a large quantity of triterpenoids. By analyzing the 
RMD values and the molecular weights, purification was successfully performed 
through several isolation steps to result in 20 compounds, among which 3 
compounds were new. As shown in Table 2, the RMD values for triterpenoids were 
closely fixed in the range between the minimum, 614.1525, and the maximum, 












Table 2. The calculations of relative mass defects (1-20) based on the MS/MS spectra.   
Theoretical Exact mass based on 
Negative Ion Mode Fragment Ion 
RMD Chemical Formula Types 
516.3451 668.3515 C31H48O6 Lupane 
468.2876 614.1525 C29H40O5 Ursane 
516.3451 668.3515 C31H48O6 Lupane 
500.3502 699.9098 C31H48O5 Lupane 
504.3451 684.2537 C30H48O6 Ursane 
456.3603 789.5078 C30H48O3 Lupane 
456.3603 789.5078 C30H48O3 Oleanane 
488.3502 717.1083 C30H48O5 Oleanane 
472.3553 752.188 C30H48O4 Oleanane 
472.3553 752.188 C30H48O4 Lupane 
442.3811 861.4744 C30H50O2 Oleanane 
470.3032 644.6905 C29H42O5 Ursane 
472.3189 675.1794 C29H44O5 Ursane 
488.3502 717.1083 C30H48O5 Oleanane 
456.3240 710.0218 C29H44O4 Ursane 
298.1205 404.199 C18H18O4 Dimethylchalcone 
284.1049 369.2298 C17H16O4 Dimethylflavanone 
298.1205 404.199 C18H18O4 Dimethylflavanone 
618.3920 633.9021 C39H54O6 Oleanane 




(a)                                                                     (b)                                                                     (c)  
 
Figure 29. Relative Mass defects (RMDs) calculations: a) C. operculatus leaves library based on scifinder search. b) n-BuOH fraction by 
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3. PTP1B inhibitory activities of isolated compounds 
PTP1B has been demonstrated as a brilliant drug target for the treatment of 
diabetes mellitus type 2 and obesity (Na et al., 2007). PTP1B enzyme assay was 
performed to all isolated compounds (1-20) for their inhibitory activities. The 
procedure is clearly described in section II.5-1. As shown in Figure 30, among all 
the isolated constituents, compounds 3, 6, 7, 9, 10, 19, and 20 significantly inhibited 
the activity against PTP1B while compound 6 had especially strong inhibitory effect 
on the enzyme.  
The structure activity relationships (SARs) were searched based on the PTP1B 
assay by the previously described literature (Jiang et al., 2012). It suggested that the 
presence of hydroxyl group and lipophilic functionalities had a significant PTP1B 
inhibitory effect among triterpenoids. For example, hydroxylation of C-2, C-19, C-
23, or C-6 decreased the activity whereas formation of double bond on C-12 and C-
13 enhanced the inhibitory effect. Moreover, the existence of C-28 as a free 
carboxylic acid instead of a lactone ring improved the activity. The position of 
methyls at C-29 and C-30 in case of ursane- and oleanane- types left the activity 
unchanged. Isolated triterpenoids, 1-15, 19, and 20, were satisfied with the above 
rules. Betulinic acid and oleanolic acid moiety usually have great chance to inhibit 








Figure 30. PTP1B Inhibitory activities of isolated compounds 1-20. 
Data were evaluated as the mean ± SD (n= 2). Characteristics were compared between groups, *p < 0.05, **p < 0.01 and ***p < 0.001 compared 













































The purpose of this research was the investigation of the triterpenoids from 
leaves of Cleistocalyx operculatus by mining LC-MS metabolites profile with 
dereplication isolating process. In addition, this research was performed exploration 
the bioactive compounds as PTP1B inhibitors to determine their inhibition properties. 
 After this promising approach for specific metabolite classes is accomplished 
by determining RMDs, the purification was successfully performed. As shown in 
Table 2, the fixed range of triterpenoids in RMD values was fully understood 
because of the isoprene as triterpene building block. The RMD of 600-800 ppm 
reflects its high hydrogen content. This range stays at the constant for the structures, 
shared the same fractional hydrogen content. This plant consists of a large amount 
of triterpenoids and was discovered the presence of highly modified and oxygenated 
triterpenoids. As a result, it has been succeeded for isolating total 20 compounds, 
including three new triterpenoids (1-3) and seventeen known compounds (4-20).  
All isolated constituents were analyzed for their PTP1B inhibitory activities. 
Among the tested compounds, the triterpenoids (3, 6, 7, 9, 10, 19, and 20) showed 
moderate effects on the inhibition activities while the compound 6 showed the most 
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수용 (Cleistocalyx operculatus (Roxb.) Merr. Et L.M. Perry.는 
도금양과(Myrtaceae)에 속하는 상록수로서 중국, 태국, 베트남, 호주 등 아시아 전역에 
널리 분포되어 있다. 수용의 잎과 꽃봉오리는 여러 문화권에서 허브 차나 전통적인 
약물로서 감기, 열, 항염, 위장질환 등 다양한 의학적 용도로 오래 전부터 사용되어 왔다. 
꽃봉오리에 대한 연구는 활발히 진행 되어 왔으며 주로 chalcone, flavonoids, 
triterpenoids, acetophenone 관련 화합물들이 암세포 성장 저지효과, 콜린에스테라아제 
억제, 항산화, 항고혈당, 항 인플루엔자, 항염 등 다양한 생리활성이 있다고 보고되었다. 
그러나 지금까지 잎에 대한 연구는 상대적으로 미비한 실정이다.  
최근에 분석 기술의 발전으로 HPLC-qTOF-MS와 같은 질량 분석기를 사용해서 
식물 추출물과 같은 복잡한 혼합물의 분석을 단순화 시키는 방법이 잇따라 등장하고 있다. 
현재까지 천연물 연구에서는 이미 많이 알려진 dereplication 기법을 통해 기존에 보고 된 
화합물을 제외하고 신규 화합물의 효과적인 분리를 진행하고 있다. 본 연구는 이 기법에 
상대적 질량 결손(RMD) 방법을 추가적으로 사용하였다. 단시간에 식물의 특정한 
대사산물의 계열을 분자와 토막이온을 통해 추측하여 수용에서 특이적인 성분군인 
pentacyclic-type triterpene 에 속하는 신규 화합물을 효과적으로 분리하여 생리활성을 
규명하는 것을 주요 목적으로 하였다.  
수용의 잎을 채집하여 50% 에탄올 추출물을 수득한 후 n-Hexane, n-BuOH 및 
H2O 층으로 분획하였다. 그 결과 triterpene 이 많이 함유되 있는 n-BuOH층에서 
데이터베이스의 값과 비교하여 새로운 화합물이라고 여겨지는 RMD 값과 MASS 값을 
가진 화합물을 가려내고, 산화가 많이 일어나고 변형된 pentacyclic-type triterpene 을 
추정하여 분리를 진행했다. 그 결과, 17종의 triterpene (1-15,19,20)과 3종의 phenolic 
compounds (16-18)을 분리하고 구조동정 하였다. 분리한 화합물 중 3종은 
pentacyclic-type triterpene (1-3)으로 천연에서 처음으로 분리보고 되는 물질이며 
각각, cleistocalyxic acid L (1), cleistocalyxolides C (2), cleistocalyxic acid M (3)로 
명명하였다. 분리된 기지화합물들의 구조는 Melaleucic acid 28-methyl ester (4), 
19α-Hydroxyasiatic acid (5), Betulinic acid (6), Oleanolic acid (7), (2a, 3b, 
12a)-Trihydroxy-olean-28-oic acid 28,13- lactone (8), Maslinic acid (9), 
Alphitolic acid (10), Erythrodiol (11), Ulmoidol (12), 2α,3β,19α-Trihydroxy-
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24-norurs- 4(23),12-dien-28-oic acid (13), Arjunolic acid (14), Ilekudinol B 
(15), 2',4'-dihydroxy-6′-methoxy-3',5'-dimethylchalcone (16), 
Demethoxymatteucinol (17), 7-hydroxy-5-methoxy-6,8-dimethylflavanone 
(18), 3-O-(E)-p-Coumaroyl maslinic acid (19), 3-O-(Z)-p-Coumaroyl 
maslinic acid (20)로 규명 되었다. 분리된 화합물은 RMD값과 Mass값의 차이로 인해 
화합물의 계열이 쉽고 빠르게 도식화하여 극명하게 나뉘는 것을 확인하였다. 
본 연구의 결과로부터 화합물의 화학적 특성을 규명하였을 뿐 아니라, 신규 화합물을 
상대적 질량 결손 방법을 통하여 새로운 화합물의 존재 가능성을 확임함으로써 수용에서의 
pentacyclic-type triterpene 화합물의 화학적 다양성을 제시하였다. 또한, 분리된 
화합물의 PTP1B 저해 활성을 확인한 결과, 화합물 6과 9 에서 강한 활성 저해를 
나타내었고, 화합물 3, 7, 10, 19,와 20 에서 적당한 활성이 있음을 확인하였다. PTP1B 
저해활성의 증진을 통해 수용의 잎이 PTP1B의 치료 물질로서의 활용가능성을 
제시하였다. 
 
주요어: Cleistocalyx operculatus (수용), 상대적 질량 결손 (RMD), cleistocalyx acid, 













































Figure S1. The LC/ESI-MS profile of isolated compounds from n-BuOH-soluble fraction of C. operculatus leaves. The system was set up with 
INNO C18 column (4.6  250 mm, 5 µm particle size) with ESI dual mode, positive & negative (CID. 150), and the solvent system was 











































































Figure S13. NOESY spectrum of compound 3 in pyridine-d5 
